Ab­b­Vie beats first-quar­ter ex­pec­ta­tions, but Hu­mi­ra guid­ance leaves an­a­lysts con­fused

Ab­b­Vie’s ef­fort to pro­tect Hu­mi­ra’s mar­ket share is get­ting ex­pen­sive.

On Fri­day, the com­pa­ny an­nounced a 40% de­cline in the megablock­buster drug’s US sales for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER